A Phase III, International, Randomized, Controlled Study of Rigosertib versus

ID Number 15-1939

Principal Investigator(s)
Lewis R Silverman

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called rigosertib when it is given to people with MDS.  An experimental drug is not approved by the United States Food and Drug Administration (FDA) for use except in research studies.

Rigosertib is being studied as a new potential anticancer drug and as a potential treatment for myelodysplasia.  Although the mechanism of action of rigosertib is not fully known it is thought to kill cancer cells by two different actions: it stops the tumor calls from dividing and blocks the proteins involved in cell division, causing cells to die.

Contact Information
Rosealie Odchimar
(212) 824-7309

Recruiting Patients: Yes